An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells

Experimental Cell Research

Volumn 240, Issue 2, 1998, Pages 312-320

  Chen, Zhe Sheng ^a   Mutoh, Masato ^b   Sumizawa, Tomoyuki ^a   Furukawa, Tatsuhiko ^a   Haraguchi, Misako ^a   Tani, Ayako ^a   Saijo, Nagahiro ^c   Kondo, Takahito ^d   Akiyama, Shin Ichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin resistance; CMOAT; GS X pump; GSH; MRP

Indexed keywords

CISPLATIN; HEAVY METAL; MULTIDRUG RESISTANCE PROTEIN;

ACTIVE TRANSPORT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; CELL STRAIN KB; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0031823946     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.3938     Document Type: Article

References (41)

1. Loehrer P. J., Einhorn L. H. Cisplatin. Ann. Intern. Med. 100:1984;704-713.
2. Timmer-Bosscha H., Mulder N. H., de Vries E. G. E. Modulation ofcis-diamminedichloroplatinum(II) resistance: A review. Br. J. Cancer. 66:1992;227-238.
3. Ishikawa T., Ali-Osman F. Glutathione-associatedcis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268:1993;20116-20125.
4. Fujii R., Mutoh M., Niwa K., Yamada K., Aikou T., Nagagawa M., Kuwano M., Akiyama S. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn. J. Cancer Res. 85:1994;426-433.
5. 4by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J. Natl. Cancer Inst. 86:1994;1781-1784.
6. Cole S. P. C., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M. V., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
7. Zaman G. J. R., Flens M. J., van Leusden M. R., de Haas M., Mulder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J., Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA. 91:1994;8822-8826.
8. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P. C., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
9. Kruh G. D., Chan A., Myers K., Gaughan K., Miki T., Aaronson S. A. Expression complementary DNA library transfer establishesmrpas a multidrug resistance gene. Cancer Res. 54:1994;1649-1652.
10. Jedlitschky G., Leier I., Buchholz U., Center M., Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 54:1994;4833-4836.
11. Leier I., Jedlitschky G., Buchholz U., Cole S. P. C., Deeley R. G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:1994;27807-27810.
12. Muller M., Meijer C., Zaman G. J. R., Borst P., Scheper R. J., Mulder N. H., de Vries E. G. E., Jansen P. L. M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA. 91:1994;13033-13037.
13. Ishikawa T., Bao J-J., Yamane Y., Akimaru K., Frindrich K., Wright C. D., Kuo M. T. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem. 271:1996;14981-14988.
14. Akiyama S., Fojo J. A., Hanover J. A., Pastan I. H., Gottesman M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 11:1985;117-126.
15. Sumizawa T., Chuman Y., Sakamoto H., Iemura K., Almquist K. C., Deeley R. G., Cole S. P. C., Akiyama S. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somat. Cell Mol. Genet. 20:1994;423-435.
16. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
17. Krishnamachary N., Center M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:1993;3658-3661.
18. Paulusma C. C., Bosma P. J., Zaman G. J. R., Bakker C. T. M., Otter M., Scheffer G. L., Scheper R. J., Borst P., Elferink R. P. J. O. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science. 271:1996;1126-1128.
19. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
20. Kyhse-Anderson J. Electroblotting of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods. 10:1984;203-209.
21. Loh S. Y., Mistry P., Kelland L. R., Abel G., Harrap K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: Circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer. 66:1992;1109-1115.
22. Andrews P. A., Velury S., Mann S. C., Howell S. B. cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:1988;68-73.
23. Mann S. C., Andrews P. A., Howell S. B. Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 25:1990;236-240.
24. Parker R. J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87:1991;772-777.
25. Goto S., Yozuhiro K., Morikawa T., Urata Y., Suzuki K., Kondo T. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res. 55:1995;4297-4301.
26. Zaman G. J. R., Lankelma J., Tellingen O. V., Beijnem J., Dekker H., Paulusma C., Elferink R. P. J. O., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA. 92:1995;7690-7694.
27. De Vries E. G. E., Muller M., Meijer C., Jansen P. L. M., Mulder N. H. J. Role of the glutathione S-conjugate pump in cisplatin resistance. Natl. Cancer Inst. 87:1995;537-538.
28. Cole S. P. C., Sparks K. E., Fraser K., Loe D. W., Grant C. E., Wilson G. M., Deeley R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
29. Chen G., Zeller W. J. In vitroinvestigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. J. Cancer Res. Clin. Oncol. 116:1990;443-447.
30. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA. 89:1992;3070-3074.
31. Perez R. P., Johnson S. W., Handel L. M., O'Dwyer P. J., Hamilton T. C. Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. Gynecol. Oncol. 58:1995;312-318.
32. Mistry P., Kelland L. R., Abel G., Sidhar S., Harrap K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer. 64:1991;215-220.
33. Richon V. M., Schulte N., Eastman A. Mutiple mechanisms of resistance tocis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res. 47:1987;2056-2061.
34. Andrews P. A., Murphy M. P., Howell S. B. Characterization of cispaltin-resistant COLO 316 human ovarian carcinoma cells. Proc. Am. Assoc. Cancer Res. 27:1986;289.
35. Naredi P., Heath D. D., Enns R. E., Howell S. B. Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J. Clin. Invest. 95:1995;1193-1198.
36. Chuman Y., Chen Z-S., Sumizawa T., Furukawa T., Haraguchi M., Takebayashi Y., Niwa K., Yamada K., Aikou T., Akiyama S. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem. Biophys. Res. Commun. 226:1996;158-165.
37. Kurokawa H., Ishida T., Nishio K., Arioka H., Sata M., Fukumoto H., Miura M., Saijo N. γ-Glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem. Biophys. Res. Commun. 216:1995;258-264.
38. Li Z-S., Szczypka M., Lu Y-P., Thiele D. J., Rea P. A. The yeast cadmium factor (YCF1) is a vacuolar glutathione S-conjugate pump. J. Biol. Chem. 271:1996;6509-6517.
39. Borst P., Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49:1995;427-460.
40. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., Kagotani K., Okumura K., Akiyama S., Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:1996;4124-4129.
41. Naredi P., Heath D. D., Enns R. E., Howell S. B. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res. 54:1994;6464-6468.